Skip to menu Skip to content Skip to footer
Professor Nikolas Haass
Professor

Nikolas Haass

Email: 
Phone: 
+61 7 344 37087

Overview

Background

I am a clinician scientist and academic leader with research in melanoma cell biology and experimental melanoma therapy. I received my degree in medicine from the University of Heidelberg, Germany (1990-1998). I graduated summa cum laude with a PhD in Cell Biology from the University of Heidelberg (1993-1999) and trained in clinical dermatology at the University of Hamburg, Germany (1999-2003). In 2003 I moved to Philadelphia, PA, to work as a post-doctoral fellow in Meenhard Herlyn’s lab at The Wistar Institute (2003-2007). From there I was recruited as an associate faculty member to the Centenary Institute/University of Sydney (2007-2013). In 2013 I commenced a position as Associate Professor for Cutaneous Oncology at University of Queensland Diamantina Institute (now Frazer Institute) and was promoted to full Professor in April 2016.

Availability

Professor Nikolas Haass is:
Available for supervision

Qualifications

  • Doctoral Diploma, Ruprecht Karls Universität Heidelberg

Research impacts

Using cutting-edge technology, including real-time cell cycle imaging in 3D culture and in vivo, my team studies the role of dynamic melanoma heterogeneity in melanomagenesis with the goal to develop novel therapeutic approaches by simultaneously targeting different tumor cell subpopulations. My laboratory and our team are in the unique position to combine sophisticated imaging and biosensor approaches with biochemical methods to provide unprecedented insight to the mechanisms of tumor heterogeneity, tumor-stroma interactions and cancer immunology.

My contribution to the field is best evidenced by 97 original papers and invited reviews in leading biomedical journals. Many of our papers have a large impact in the field (>7500 citations in total, and 19 papers cited >100 times each). The papers in Mol Cancer Ther (2006, cited >500x), Cancer Res (2007, cited 265x) and PNAS (2008, cited 1500x) were evaluated by Faculty 1000 Biology as recommended or exceptional, respectively.

Works

Search Professor Nikolas Haass’s works on UQ eSpace

217 works between 1996 and 2024

81 - 100 of 217 works

2016

Journal Article

Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer

Maadi, Hamid, Moshtaghian, Abdolvahab, Taha, Masoumeh Fakhr, Mowla, Seyed Javad, Kazeroonian, Asiye, Haass, Nikolas K. and Javeri, Arash (2016). Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer. International Journal of Biochemistry and Cell Biology, 81 (A), 121-132. doi: 10.1016/j.biocel.2016.11.004

Multimodal tumor suppression by miR-302 cluster in melanoma and colon cancer

2016

Journal Article

JNK-ERK signalling in melanoma: rewired or entangled?

Haass, N. K. (2016). JNK-ERK signalling in melanoma: rewired or entangled?. British Journal of Dermatology, 175 (6), 1139-1140. doi: 10.1111/bjd.14903

JNK-ERK signalling in melanoma: rewired or entangled?

2016

Journal Article

Zielgerichtete Melanomtherapie – Die Rolle der dynamischen Tumorheterogenität

Haass, Nikolas K. (2016). Zielgerichtete Melanomtherapie – Die Rolle der dynamischen Tumorheterogenität. Spectrum Dermatologie, 2016 (3), 14-17.

Zielgerichtete Melanomtherapie – Die Rolle der dynamischen Tumorheterogenität

2016

Journal Article

Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer

Skalamera, Dubravka, Dahmer-Heath, Mareike, Stevenson, Alexander J., Pinto, Cletus, Shah, Esha T., Daignault, Sheena M., Said, Nur Akmarina B. M., Davis, Melissa, Haass, Nikolas K., Williams, Elizabeth D., Hollier, Brett G., Thompson, Erik W., Gabrielli, Brian and Gonda, Thomas J. (2016). Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer. Oncotarget, 7 (38), 61000-61020. doi: 10.18632/oncotarget.11314

Genome-wide gain-of-function screen for genes that induce epithelial-to-mesenchymal transition in breast cancer

2016

Journal Article

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

Beaumont, Kimberley A., Hill, David S., Daignault, Sheena M., Lui, Goldie Y. L., Sharp, Danae M., Gabrielli, Brian, Weninger, Wolfgang and Haass, Nikolas K. (2016). Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. Journal of Investigative Dermatology, 136 (7), 1479-1489. doi: 10.1016/j.jid.2016.02.805

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

2016

Journal Article

microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB

Giles, Keith M., Brown, Rikki A. M., Ganda, Clarissa, Podgorny, Melissa J., Candy, Patrick A., Wintle, Larissa C., Richardson, Kirsty L., Kalinowski, Felicity C., Stuart, Lisa M., Epis, Michael R., Haass, Nikolas K., Herlyn, Meenhard and Leedman, Peter J. (2016). microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget, 7 (22), 31663-31680. doi: 10.18632/oncotarget.9421

microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB

2016

Conference Publication

Developing a new melanoma drug

Stehn, J. R., Stevenson, A., Spoerri, L., Daignault, S. M., Gabrielli, B., Eiffe, E., Gunning, P. W. and Haass, N. (2016). Developing a new melanoma drug. HOBOKEN: WILEY-BLACKWELL.

Developing a new melanoma drug

2016

Conference Publication

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

Beaumont, K., Hill, D., Daignault, S., Sharp, D., Gabrielli, B., Weninger, W. and Haass, N. (2016). Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells. Annual Meeting of the Society-for-Investigative-Dermatology (SID), Scottsdale, AZ, United States, 11-14 May 2016. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.jid.2016.02.695

Cell cycle phase-specific drug resistance as an escape mechanism of melanoma cells

2016

Journal Article

In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis

Vaidyanathan, Srividya, Cato, Kathleen, Tang, Lu, Pavey, Sandra, Haass, Nikolas K., Gabrielli, Brian G. and Duijf, Pascal H. G. (2016). In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis. Oncogene, 35 (41), 5446-5455. doi: 10.1038/onc.2016.94

In vivo overexpression of Emi1 promotes chromosome instability and tumorigenesis

2016

Conference Publication

Real-time cell cycle and cell death imaging of the effect of sphingosine kinase inhibition on 3D melanoma spheroids

Kienzle, A., McGowan, E., Douglas, G., Kaczorowski, D., Weninger, W. and Haass, N. K. (2016). Real-time cell cycle and cell death imaging of the effect of sphingosine kinase inhibition on 3D melanoma spheroids. 43rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung-e-V (ADF), Vienna Austria, Mar 10-12, 2016. HOBOKEN: WILEY-BLACKWELL.

Real-time cell cycle and cell death imaging of the effect of sphingosine kinase inhibition on 3D melanoma spheroids

2016

Conference Publication

MITF regulates cell adhesion and subcompartment-specific distribution of differentially cycling melanoma cells

Tonnessen, C. A., Beaumont, K. A., Spoerri, L., Hill, D. S., Jurek, R. J., Daignault, S. M., Ahmed, F., Fane, M., Smith, A., Weninger, W. and Haass, N. K. (2016). MITF regulates cell adhesion and subcompartment-specific distribution of differentially cycling melanoma cells. 43rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung-e-V (ADF), Vienna Austria, Mar 10-12, 2016. HOBOKEN: WILEY-BLACKWELL.

MITF regulates cell adhesion and subcompartment-specific distribution of differentially cycling melanoma cells

2016

Conference Publication

Cell cycle phase determines efficacy of bortezomib, temozolomide and MAPK inhibitor-induced apoptosis in melanoma

Hill, D. S., Beaumont, K. A., Daignault, S. M., Sharp, D. M., Gabrielli, B., Weninger, W. and Haass, N. K. (2016). Cell cycle phase determines efficacy of bortezomib, temozolomide and MAPK inhibitor-induced apoptosis in melanoma. 43rd Annual Meeting of the Arbeitsgemeinschaft-Dermatologische-Forschung-e-V (ADF), Vienna Austria, Mar 10-12, 2016. HOBOKEN: WILEY-BLACKWELL.

Cell cycle phase determines efficacy of bortezomib, temozolomide and MAPK inhibitor-induced apoptosis in melanoma

2016

Conference Publication

MITF modifies invasion and characteristics of the epithelial to mesenchymal transition in melanoma

Daignault, S. M., Tonnessen, C. A., Ahmed, F., Spoerri, L. and Haass, N. K. (2016). MITF modifies invasion and characteristics of the epithelial to mesenchymal transition in melanoma. Asia-Pacific Combined Dermatology Research Conference 2016, Noosa, QLD Australia, 25–28 August 2016. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia.

MITF modifies invasion and characteristics of the epithelial to mesenchymal transition in melanoma

2016

Conference Publication

Overexpression of Early Mitotic Inhibitor 1 (Emi1) promotes genomic instability and cancer

Vaidyanathan, S., Cato, K., Tang, L., Pavey, S., Haass, N. K., Gabrielli, B. G. and Duijf, P. H. G. (2016). Overexpression of Early Mitotic Inhibitor 1 (Emi1) promotes genomic instability and cancer. Annual Meeting of the American Society for Cell Biology (ASCB), San Francisco Ca, Dec 03-07, 2016. BETHESDA: American Society for Cell Biology.

Overexpression of Early Mitotic Inhibitor 1 (Emi1) promotes genomic instability and cancer

2016

Conference Publication

Stress induced multi-drug tolerance precedes acquired drug resistance in melanoma

Schaider, H., Menon, D. R., Emran, A., Gabrielli, B., Haass, N., Somasundaram, R. and Herlyn, M. (2016). Stress induced multi-drug tolerance precedes acquired drug resistance in melanoma. 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Barcelona Spain, 18-21 November 2014. Richmond, VIC Australia: Wiley-Blackwell .

Stress induced multi-drug tolerance precedes acquired drug resistance in melanoma

2016

Conference Publication

Identification of unique molecular signatures of differentially cycling tumour cell subpopulations in a 3D melanoma model

Ahmed, F., Tonnessen, C., Spoerri, L., Daignault, S., Stark, M., Schaider, H., Hill, M. and Haass, N. (2016). Identification of unique molecular signatures of differentially cycling tumour cell subpopulations in a 3D melanoma model. Asia-Pacific Combined Dermatology Research Conference 2016, Noosa, QLD Australia, 25–28 August 2016. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia. doi: 10.1111/ajd.12584

Identification of unique molecular signatures of differentially cycling tumour cell subpopulations in a 3D melanoma model

2016

Conference Publication

Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity

Nierfeld, M., Nascimento, P. R., Baesler, K., Knuever, J., Spoerri, L., Schaider, H., Weninger, W. and Haass, N. K. (2016). Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity. Asia-Pacific Combined Dermatology Research Conference 2016, Noosa, QLD Australia, 25–28 August 2016. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia.

Rose Bengal melanoma therapy - phototoxicity versus intrinsic cytotoxicity

2016

Conference Publication

Rab27a regulates invadopodia activity and invasion in melanoma

Haass, N. K., Lui, G. Y., Sharp, D. M., Tan, S. -Y., Weninger, W. and Beaumont, K. A. (2016). Rab27a regulates invadopodia activity and invasion in melanoma. Asia-Pacific Combined Dermatology Research Conference 2016, Noosa, QLD Australia, 25–28 August 2016. Richmond, VIC Australia: Wiley-Blackwell Publishing Asia.

Rab27a regulates invadopodia activity and invasion in melanoma

2015

Journal Article

Imaging- and flow cytometry-based analysis of cell position and the cell cycle in 3d melanoma spheroids

Beaumont, Kimberley A., Anfosso, Andrea, Ahmed, Farzana, Weninger, Wolfgang and Haass, Nikolas K. (2015). Imaging- and flow cytometry-based analysis of cell position and the cell cycle in 3d melanoma spheroids. Journal of Visualized Experiments, 106 (e53486) e53486, e53486. doi: 10.3791/53486

Imaging- and flow cytometry-based analysis of cell position and the cell cycle in 3d melanoma spheroids

2015

Journal Article

Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS

Ke, Yazi D., van Hummel, Annika, Stevens, Claire H., Gladbach, Amadeus, Ippati, Stefania, Bi, Mian, Lee, Wei S., Kruger, Sarah, van der Hoven, Julia, Volkerling, Alexander, Bongers, Andre, Halliday, Glenda, Haass, Nikolas K., Kiernan, Matthew, Delerue, Fabien and Ittner, Lars M. (2015). Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathologica, 130 (5), 661-678. doi: 10.1007/s00401-015-1486-0

Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS

Funding

Current funding

  • 2023 - 2024
    Changing the melanoma tumour microenvironment to improve both targeted and immune therapy
    Australasian College of Dermatologists Scientific Research Fund
    Open grant

Past funding

  • 2022 - 2023
    Laser capture microdissection to empower cancer discoveries, improve diagnosis, treatment and outcomes in amyloidosis patients
    IPF Healthy - Medical Research
    Open grant
  • 2020 - 2023
    Mathematical models of 4D multicellular spheroids (ARC Discovery Project administered by Queensland University of Technology)
    Queensland University of Technology
    Open grant
  • 2019
    Improving Immune Checkpoint Therapy of Melanoma
    Australasian College of Dermatologists Scientific Research Fund
    Open grant
  • 2019 - 2022
    Induction of endoplasmic reticulum stress to potentiate immunogenic cell death to improve melanoma therapy
    Cancer Council Queensland
    Open grant
  • 2018 - 2022
    Improving outcomes for patients with melanoma brain metastases using novel personalised and response-adapted treatment strategies (PARF Translation Research Innovation Award administered by MSHHS)
    Metro South Hospital and Health Service
    Open grant
  • 2017 - 2024
    ACRF Cancer Ultrastructure and Function Facility
    Australian Cancer Research Foundation
    Open grant
  • 2017 - 2019
    Melanoma environment and heterogeneity in therapy sensitivity and resistance - Haass
    Meehan Bequest
    Open grant
  • 2017 - 2018
    Personalized medicine for renal cell carcinoma patients: use of patient-derived tumors for 3-D cell culture and animal models
    UQ-Ochsner Seed Fund for Collaborative Research - MABS funds
    Open grant
  • 2016
    Epigenetic remodelling driving acquired permanent drug resistance in melanoma cells
    PA Research Foundation
    Open grant
  • 2015 - 2018
    Defining the role of Microphthalmia-associated Transcription Factor (MITF) in melanoma heterogeneity by real-time cell cycle imaging
    NHMRC Project Grant
    Open grant
  • 2015
    Next-generation cell analysis: Automated high-throughput 3D microscope and multimode microplate reader
    NHMRC Equipment Grant
    Open grant
  • 2014
    Purchase of low O2 incubator and Dissociator
    NHMRC Equipment Grant
    Open grant
  • 2013 - 2014
    Real-time Imaging of cell cycle progression in melanoma
    NHMRC Project Grant
    Open grant

Supervision

Availability

Professor Nikolas Haass is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

Completed supervision

Media

Enquiries

For media enquiries about Professor Nikolas Haass's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au